Dosing in Heavy-weight/Obese Patients with the LMWH, Tinzaparin: A Pharmacodynamic Study

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Thrombosis and Haemostasis

• Publication date

  2002-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/s-0037-1613090PMID 12038783
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dosing and Monitoring of Low‐Molecular‐Weight Heparins in Special Populations

  2001cited by this paper
• Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.

  2001cited by this paper
• Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.

  2001cited by this paper
• Effect of Patient Weight on the Anticoagulant Response to Adjusted Therapeutic Dosage of Low-Molecular- Weight Heparin for the Treatment ofVenous Thromboembolism

  2001cited by this paper
• Low-molecular-weight heparins: pharmacologic profile and product differentiation.

  1998cited by this paper
• Varying body mass index cutoff points to describe overweight prevalence among U.S. adults: NHANES III (1988 to 1994).

  1997cited by this paper
• A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.

  1993cited by this paper
• Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.

  1992cited by this paper
• Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers.

  1991cited by this paper
• Effects of an Enzymatically Depolymerized Heparin as Compared with Conventional Heparin in Healthy Volunteers

  1987influential reference

• Pulmonary embolism prophylaxis and treatment: What's right, what's wrong, and the future

  2025cites this paper
• A Multicenter Prospective Cohort Study on the Use of Weight‐Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer‐Associated Venous Thromboembolism—The WAVe Study

  2025cites this paper
• Delphi Consensus Among French Obesity Experts on Clinical Recommendations for Drug Prescription in Patients With Severe Obesity

  2025cites this paper
• Venous thromboembolism in pregnant obese Individuals.

  2024cites this paper
• Unresolved questions on venous thromboembolic disease. Venous thromboembolism (VTE) management in obese patients. Consensus statement of the French Society of Vascular Medicine (SFMV).

  2024cites this paper
• SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023)

  2024cites this paper
• A systematic review of therapeutic enoxaparin dosing in obesity

  2024cites this paper
• Weight-adjusted dosing of tinzaparin for thromboprophylaxis in obese medical patients

  2023influential citation
• Tinzaparin—a review of its molecular profile, pharmacology, special properties, and clinical uses

  2022cites this paper
• Body weight adapted tinzaparin treatment in patients with obesity.

  2022cites this paper
• Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus

  2021cites this paper
• Treatment of thrombosis

  2020cites this paper
• Modern pharmacological treatment of obese patients

  2020cites this paper
• Prise en charge diagnostique et thérapeutique de la maladie veineuse thromboembolique chez le patient obèse

  2020cites this paper
• Low Molecular Weight Heparin

  2020cites this paper
• Dosage of Anticoagulants in Obesity: Recommendations Based on a Systematic Review

  2020cites this paper
• Comparing low-molecular-weight heparin dosing for treatment of venous thromboembolism in patients with obesity (RIETE registry).

  2020cites this paper
• Weight‐adjusted tinzaparin for the prevention of venous thromboembolism after bariatric surgery

  2018cites this paper
• Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus.

  2018cites this paper
• Anticoagulation at the extremes of body weight: choices and dosing

  2018cites this paper
• Unfractionated Heparin and Low-Molecular-Weight Heparin

  2018cites this paper
• American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.

  2018cites this paper
• Novel insights and developments in thrombosis and haemostasis

  2017cites this paper
• Empirically Reduced Dosages of Tinzaparin in Patients with Moderate-to-Severe Renal Insufficiency Lead to Inadequate Anti-Xa Levels

  2017cites this paper
• Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux

  2016cites this paper
• ASHP Therapeutic Position Statements 569 ASHP Therapeutic Position Statement on the Role of Pharmacotherapy in Preventing Venous Thromboembolism in Hospitalized Patients Position

  2016cites this paper
• The use of anticoagulants for the treatment and prevention of venous thromboembolism in obese patients: implications for safety

  2016influential citation
• Low-Molecular-Weight Heparin Prophylaxis Dosing

  2016cites this paper
• Haemostatic safety in epidural analgesia

  2016cites this paper
• The use of anticoagulants in morbidly obese patients.

  2016cites this paper
• Heparins in cancer-associated venous thrombosis.

  2016cites this paper
• Besonderheiten der Pharmakotherapie adipöser Patienten

  2015cites this paper
• Clinical Pharmacology of Frequently Used Intravenous Drugs During Bariatric Surgery in Adolescents.

  2015cites this paper
• Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis.

  2015cites this paper
• Monitoring Low Molecular Weight Heparins at Therapeutic Levels: Dose-Responses of, and Correlations and Differences between aPTT, Anti-Factor Xa and Thrombin Generation Assays

  2015cites this paper
• Fixed-Dose Enoxaparin After Bariatric Surgery: The Influence of Body Weight on Peak Anti-Xa Levels

  2015cites this paper
• Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review.

  2015cites this paper
• Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment.

  2015cites this paper
• Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

  2014cites this paper
• Pharmakokinetische Besonderheiten bei adipösen Patienten

  2014cites this paper
• Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint

  2014cites this paper
• Weight-adjusted LMWH prophylaxis provides more effective thrombin inhibition in morbidly obese pregnant women.

  2014cites this paper
• The influence of morbid obesity on the pharmacokinetics and pharmacodynamics of drugs in adolescents and adults : focus on propofol and nadroparin.

  2013cites this paper
• Pharmacologic prevention of venous thromboembolism in obese patients

  2013cites this paper
• Pharmacokinetic Parameter Changes Observed in Obese Patients Changes Observed in Bariatric Surgery Patients

  2013cites this paper
• Thromboseprophylaxe in der bariatrischen Chirurgie Thrombosis prophylaxis in bariatric surgery

  2013cites this paper
• Thrombosis prophylaxis in bariatric surgery Evaluation of the situation and practical recommen- dations

  2013cites this paper
• Prediction and prevention of venous thrombosis in pregnancy

  2013cites this paper
• Clinical Use of Anti-Xa Monitoring in Malignancy-Associated Thrombosis

  2013cites this paper
• Adjustments in the diagnostic work-up , treatment and prognosis of pulmonary embolism

  2013cites this paper
• ASHP therapeutic position statement on the role of pharmacotherapy in preventing venous thromboembolism in hospitalized patients.

  2012cites this paper
• Venous Thromboembolism – Prophylaxis and Treatment

  2012cites this paper
• Evidence-Based Clinical Practice Guidelines ed: American College of Chest Physicians Therapy and Prevention of Thrombosis, 9th Parenteral Anticoagulants : Antithrombotic

  2012cites this paper
• Unfractionated Heparin and Low Molecular Weight Heparin in Ischemic Heart Disease

  2012cites this paper
• Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cites this paper
• Management of Venous Thromboembolism in the Critically Ill Obese Patient

  2012cites this paper
• Tinzaparin versus dalteparin for periprocedure prophylaxis of thromboembolic events in hemodialysis patients: a randomized trial.

  2012cites this paper
• Tinzaparin Sodium

  2012cites this paper
• Low‐molecular‐weight heparin in patients with advanced cirrhosis

  2011cites this paper
• Deep Venous Thrombosis and Pulmonary Embolism

  2011cites this paper
• Anticoagulating obese patients in the modern era

  2011cites this paper
• How to prevent, treat, and overcome current clinical challenges of VTE

  2011cites this paper
• Tinzaparin Sodium

  2010cites this paper
• Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients.

  2010influential citation
• Established venous thromboembolism therapies: heparin, low molecular weight heparins, and vitamin K antagonists, with a discussion of heparin-induced thrombocytopenia.

  2010cites this paper
• Prevention of venous thromboembolism in obesity

  2010cites this paper
• Using low molecular weight heparin in special patient populations

  2010cites this paper
• Effect of Obesity on the Pharmacokinetics of Drugs in Humans

  2010cites this paper
• 88 – What Are the Special Considerations in the Management of Morbidly Obese Patients in the Intensive Care Unit?

  2010cites this paper
• Obesity in the intensive care unit.

  2009cites this paper
• Influence of Overweight and Obesity on Medication

  2009cites this paper
• Treatment of Pulmonary Embolism in an Extremely Obese Patient

  2009cites this paper
• Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study).

  2009cites this paper
• Treatment dosing of low-molecular-weight heparins and the dose cap dilemma: considerations for patients in Canada.

  2009cites this paper
• Postoperatives Management bei Patienten mit einem BMI > 40 kg / m2

  2009cites this paper
• Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cites this paper
• Considerations in using anticoagulant therapy in special patient populations.

  2008cites this paper
• Chapter 21 – Principles of Drug Dosing in Critically Ill Patients

  2008cites this paper
• A review of the practical advantages of low molecular weight heparin in the treatment of cancer-related venous thromboembolism.

  2008cites this paper
• Diagnosis, Treatment, and Prevention of Cancer-Related Venous Thrombosis

  2008cites this paper
• Practice Guidelines (8th Edition) Clinical of Chest Physicians Evidence-Based Parenteral Anticoagulants: American College

  2008cites this paper
• Thromboprophylaxis in pregnancy: Do we need new Guidelines?

  2007cites this paper
• Venous thromboembolism in bariatric surgery patients: an update of risk and prevention.

  2007cites this paper
• Assessing, preventing, and treating venous thromboembolism: evidence-based approaches.

  2007cites this paper
• Obesity in critical care

  2007cites this paper
• Prophylaxis of Thromboembolism in Bariatric Surgery with Parnaparin

  2007cites this paper
• Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice

  2007cites this paper
• [Intermittent compression devices for swelling reduction and thrombosis prophylaxis--a pilot study after total hip replacement. Is the 2 hour daily minimum application sufficient?].

  2006cites this paper
• Die intermittierende Impulskompression zur Abschwellung und Thromboseprophylaxe – Pilotstudie nach Hüft-TEP

  2006cites this paper
• Low-molecular-weight heparins in thrombosis and cancer: emerging links.

  2006cites this paper
• Safety Profile of Different Low-Molecular Weight Heparins Used at Therapeutic Dose

  2005cites this paper
• Dosage of enoxaparin among obese and renal impairment patients.

  2005cites this paper
• Enoxaparin for Thromboprophylaxis in Morbidly Obese Patients Undergoing Bariatric Surgery: Findings of the Prophylaxis Against VTE Outcomes in Bariatric Surgery Patients Receiving Enoxaparin (PROBE) Study

  2005cites this paper
• Anticoagulation in special patient populations: are special dosing considerations required?

  2005cites this paper
• Low-Molecular-Weight Heparin for the Treatment of Venous Thromboembolism in the Elderly

  2005cites this paper
• Elevation of plasma von Willebrand factor and tumor necrosis factor-a in obese subjects and their reduction by the low molecular weight heparin tinzaparin.

  2005cites this paper
• Anticoagulant Management of Patients Undergoing Elective Surgery who Require Temporary Interruption of Warfarin Therapy

  2005cites this paper
• The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE)

  2005cites this paper
• Low molecular weight heparin in pregnancy: current issues

  2005cites this paper
• Dose capping enoxaparin is unjustified and denies patients with acute coronary syndromes a potentially effective treatment.

  2005cites this paper